Phase I trial of GLIADEL [carmustine polifeprosan 20 wafer] and O(6)-benzylguanine in pediatric patients with recurrent malignant gliomas

Trial Profile

Phase I trial of GLIADEL [carmustine polifeprosan 20 wafer] and O(6)-benzylguanine in pediatric patients with recurrent malignant gliomas

Discontinued
Phase of Trial: Phase I

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs Benzylguanine (Primary) ; Carmustine polifeprosan 20 wafer
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 20 Oct 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 20 Oct 2009 Actual patient number (3) added as reported by ClinicalTrials.gov.
    • 25 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top